Ruxolitinib with RICRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Sponsor:

Arkansas Children's Hospital Research Institute

Code:

NCT07252050

Conditions

Sickle Cell Disease

Hematopoetic Stem Cell Transplant

Haploidentical Hematopoietic Stem Cell Transplant

Haploidentical Stem Cell Transplantation

Graft Failure

Eligibility Criteria

Sex: All

Age: 12 - 45

Healthy Volunteers: Not accepted

Interventions

Ruxolitinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Arkansas Children's Hospital Research Institute on 2026-06-04.